QGEN vs TMO
QGEN: QIAGEN provides essential sample and assay technologies used by laboratories worldwide to extract and analyze molecular information from biological samples. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | QGEN | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $44.53 | $651.98 | |
| Market cap | $8.9B | $241.1B | |
| P/E as of 2026-10-08 | 23.58 | 35.10 | QGEN lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 169.13 | |
| Net margin FY2025, SEC XBRL | +20.3% | +15.0% | QGEN higher |
| Gross margin FY2025, SEC XBRL | +62.2% | n/a | |
| Operating margin FY2025, SEC XBRL | +22.3% | +17.4% | QGEN higher |
| ROE FY2025, SEC XBRL | +11.2% | +12.6% | TMO higher |
| ROA FY2025, SEC XBRL | +6.8% | +6.1% | QGEN higher |
| Debt / equity as of 2026-09-02 | 0.49 | 0.81 | QGEN lower |
| Revenue growth (YoY) as of 2026-09-02 | +4.8% | +7.2% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | -0.8% | -0.3% | TMO higher |
| Dividend yield as of 2026-09-02 | +0.8% | +0.3% | QGEN higher |
| Dividend streak (yrs) SEC XBRL | 1 | 14 | TMO higher |
| Beta as of 2026-09-02 | 0.50 | 0.77 | |
| 1-year return as of 2026-10-08 close | -6.8% | +21.6% | TMO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.